The autologous stem cell and non stem cell therapies market was valued at USD 2.75 Billion in 2024, driven by the rising incidence of chronic diseases such as cardiovascular conditions, diabetes, neurological disorders, and musculoskeletal disorders across the globe. The market is anticipated to grow at a CAGR of 9.90% during the forecast period of 2025-2034, with the values likely to reach USD 7.07 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is expected to grow significantly due to advances in regenerative medicine, offering innovative solutions for chronic diseases and tissue repair.
Non-stem cell therapies are likely to experience robust demand, driven by breakthroughs in gene therapy, biologics, and targeted treatments for various chronic and age-related conditions.
Increasing patient preference for personalised, minimally invasive treatments, along with growing healthcare investments, will propel the market for both autologous stem cell and non-stem cell therapies in the coming years.
Autologous stem cell therapies involve using a patient's stem cells to treat various conditions, promoting tissue repair and regeneration. Non-stem cell therapies, on the other hand, include treatments like biologics, gene therapies, and monoclonal antibodies that target specific diseases. Both types are gaining momentum for their effectiveness in treating chronic, autoimmune, and degenerative conditions, driving market growth.
Continuous Advancements Positively Impacting Market Value
The growing demand for personalised treatments and advancements in regenerative medicine are key drivers supporting the growth of the market. For instance, in November 2024, GIOSTAR, a leader in stem cell research, announced that the U.S. FDA had cleared its IND application for a Phase-2 clinical trial using autologous mesenchymal stem cells to treat Type II diabetes. This innovative approach offers a promising solution to alleviate disease-induced damage, presenting a new treatment alternative with minimal side effects. The approval is poised to accelerate the adoption of autologous stem cell therapies in the diabetes treatment space, contributing to market expansion during the forecast period.
Stem Cell and Gene Therapy Innovations to Impact the Autologous Stem Cell and Non Stem Cell Therapies Market Size Positively
Key market drivers such as advancements in gene therapy and the growing need for rare disease treatments are propelling the non-stem cell therapy market forward. For instance, in March 2024, Orchard Therapeutics (now part of Kyowa Kirin) received FDA approval for Lenmeldy (atidarsagene autotemcel) to treat early-onset metachromatic leukodystrophy (MLD) in children. This approval marks a significant milestone for gene therapy, offering a potential cure for a severe, rare disease. The entry of Lenmeldy into the market is expected to enhance growth in the gene therapy segment, boosting overall market development and accelerating the uptake of advanced non-stem cell treatments in the coming years.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Indication to Witness Significant Growth
Cancer indications are expected to hold the largest market share in the autologous stem cell and non-stem cell therapies market. This is due to the increasing prevalence of cancer globally, coupled with the effectiveness of stem cell-based treatments, such as CAR-T therapies, and non-stem cell solutions, like targeted immunotherapies, in improving patient outcomes.
Based on region, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States holds a significant market share due to advanced healthcare infrastructure, strong research and development capabilities, and high patient demand for innovative therapies. A favourable regulatory environment and substantial investments in biotechnology further support its dominance in the market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Foster City, California, Gilead Sciences was established in 1987. The company focuses on advanced therapies, including autologous stem cell treatments, aimed at addressing cancer, viral diseases, and immunological conditions. Its portfolio includes cell therapies for oncology, along with an expanding range of non-stem cell therapies targeting chronic diseases and immune system disorders.
Founded in 1887 and based in New York, Bristol-Myers Squibb is a global biopharmaceutical company. The company is involved in both autologous stem cell and non-stem cell therapies, particularly in oncology and immunology. It develops innovative treatments, including CAR-T cell therapies and monoclonal antibodies, to address complex diseases like cancer, cardiovascular, and autoimmune disorders.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson is a global leader in healthcare. The company’s portfolio spans a wide range of therapies, including autologous stem cell-based treatments for regenerative medicine and non-stem cell solutions like biologics and immunotherapies. Johnson & Johnson targets areas such as orthopaedics, neurology, and oncology with its innovative treatments.
Founded in 2011 and based in San Carlos, California, IOVANCE Biotherapeutics focuses on autologous T-cell therapies for cancer treatment. Specialising in tumour-infiltrating lymphocyte (TIL) therapies, the company is advancing treatments for melanoma, cervical cancer, and other solid tumours. Iovance's innovative approach aims to enhance the body’s immune response using personalised cell-based therapies to fight cancer.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Vericel and Novartis AG.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share